Nanotechnologies in Russia

, Volume 9, Issue 9–10, pp 571–576 | Cite as

Silver-nanoparticle exposure on immune system of mice depending on the route of administration

  • O. V. Kalmantaeva
  • V. V. Firstova
  • V. D. Potapov
  • E. V. Zyrina
  • V. N. Gerasimov
  • E. A. Ganina
  • V. A. Burmistrov
  • A. V. Borisov


In this study we have identified the influence of Argovit on the immune system of mice after inhalation or intragastric or subcutaneous administration. Argovit is a preparation of polyvinylpyrrolidone-coated (43.6 ± 10.7 nm) silver nanoparticles. We have found no toxic effect on the immune cells and organs, changes in T- and B-lymphocytes quantity in the spleen, or proinflammatory cytokine production after exposure to silver nanoparticles through inhalation or intragastrically. The subcutaneous administration of silver nanoparticles has changed the ratio of lymphocyte subpopulations, increased the quantity of IFN-γ-producing T-lymphocytes 3.6-fold compared with the control, and increased the content of IFN-γ in the serum of mice to 125 ± 9.2 pg/mL compared to the control (74.5 ± 6.4 pg/mL).


Silver Nanoparticles Blood Serum Subcutaneous Administration Inguinal Lymph Node Lymphocyte Subpopulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E. J. Coligan, Short Protocols in Immunology: a Compendium of Methods from Current Protocols in Immunology, Ed. by E. J. Coligan, E. B. Bierer, H. D. Margulies, E. M. Shevach, and W. Stroder (John Wiley and Sons, Hoboken, NJ, 2005).Google Scholar
  2. 2.
    W. H. De Jong, L. M. Van Der Ven, A. Sleijffers, M. V. D. Z. Park, E. H. J. M. Jansen, H. Van Loveren, and R. J. Vandebriel, “Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats,” Biomaterials 34(33), 8333–8343 (2013).CrossRefGoogle Scholar
  3. 3.
    A. E. Hawley, S. S. Davis, and L. Illum, “Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics,” Adv. Drug Deliv. Rev. 17, 129–148 (1995).CrossRefGoogle Scholar
  4. 4.
    M. Higuchi, A. Fokin, T. N. Masters, F. Robicsek, and G. W. Schmid-Schonbein, “Transport of colloidal particles in lymphatics and vasculature after subcutaneous injection,” J. Appl. Physiol. 86, 1381–1387 (1999).Google Scholar
  5. 5.
    F. Ikomi, G. K. Hanna, and G. W. Schmid-Schonbein, “Size- and surface-dependent uptake of colloid particles into the lymphatic system,” Lymphology 32, 90–102 (1999).Google Scholar
  6. 6.
    S. H. E. Kaufmann, Methods in Microbiology, Vol. 32: Immunology of Infection, Ed. by S. H. E. Kaufmann and D. Kabelitz, 2nd ed. (Acad. Press, London, 2002).Google Scholar
  7. 7.
    M. Korani, S. M. Rezayat, K. Gilani, BidgoliS. Arbabi, and S. Adeli, “Acute and subchronic dermal toxicity of nanosilver in guinea pig,” Int. J. Nanomed. 6, 855–862 (2011).CrossRefGoogle Scholar
  8. 8.
    K. Loeschner, N. Hadrup, K. Qvortrup, A. Larsen, X. Gao, U. Vogel, A. Mortensen, H. Rye Lam, and E. H. Larsen, “Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate,” Part. Fibre Toxicol. 8(18) (2011). doi:10.1186/1743-8977-8-18Google Scholar
  9. 9.
    T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” J. Immunol. Methods 65(1–2), 55–63 (1983).CrossRefGoogle Scholar
  10. 10.
    “Nanosilver: safety, health and environmental effects and role in antimicrobial resistance,” in Proc. 4th Plenary of Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) (European Commission, Dec. 12, 2013).Google Scholar
  11. 11.
    K. C. Nguyen, V. L. Seligy, A. Massarsky, T. W. Moon, P. Rippstein, J. Tan, and A. F. Tayabali, “Comparison of toxicity of uncoated and coated silver nanoparticles,” J. Phys.: Conf. Ser. 429, 012025 (2013).Google Scholar
  12. 12.
    E. J. Park, E. Baeb, J. Yib, Y. Kimc, K. Choid, S. H. Leed, J. Yoond, B. C. Leed, and K. Park, “Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles,” Environ. Toxicol. Pharmacol. 30, 162–168 (2010).CrossRefGoogle Scholar
  13. 13.
    R. Rustogi, J. Mill, J. F. Fraser, and R. M. Kimble, “The use of Acticoat TM in neonatal burns,” Burns 31, 878–882 (2005).CrossRefGoogle Scholar
  14. 14.
    L. V. Stebounova, A. Adamcakova, J. S. Kim, H. Park, O’Shaughnessy P.T., V. H. Grassian and P. S. Thorne, “Nanosilver indiced minimal lung toxicity or inflammation in a subacute murine inhalation model,” Part. Fibre Toxicol. 8(5) (2011). doi:10.1186/1743-8977-8-5Google Scholar
  15. 15.
    J. Tang, L. Xiong, S. Wang, J. Wang, L. Liu, J. Li, F. Yuan, and T. Xi, “Distribution, translocation and accumulation of silver nanoparticles in rats,” J. Nanosci. Nanotechnol. 9(8), 4924–4932 (2009).CrossRefGoogle Scholar
  16. 16.
    M. Van Der Zande, R. J. Vandebriel, E. Van Doren, E. Kramer, Z. Herrera Rivera, C. S. Serrano-Rojero, E. R. Gremmer, J. Mast, R. J. Peters, P. C. Hollman, P. J. Hendriksen, H. J. Marvin, A. A. Peijnenburg, and H. Bouwmeester, “Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure,” ACS Nano. 6 (8), 7427–7442 (2012).CrossRefGoogle Scholar
  17. 17.
    S. W. P. Wijnhoven, W. J. G. M. Peijnenburg, C. A. A. Herberts, W. I. Hagens, A. G. Oomen, E. H. W. Heugens, B. Roszek, J. Bisschops, I. Gosens, D. Van De Meent, S. Dekkers, W. H. De Jong, M. Van Zijverden, A. J. A. M. Sips, and R. Geertsma, “Nano-silver-a review of available data and knowledge gaps in human and environmental risk assessment,” Nanotoxicology 3(2), 109–138 (2009).CrossRefGoogle Scholar
  18. 18.
    S. C. Yah, S. G. Simate, and E. S. Iyuke, “Nanoparticles toxicity and their routes of exposures,” Pakistan J. Pharmaceut. Sci. 25(2), 477–491 (2012).Google Scholar
  19. 19.
    S. Zolnik Banu, A. Gonzalez-Fernandez, N. Sadrieh, and M. A. Dobrovolskai, “Minireview: nanoparticles and the immune system,” Endocrinology 151(2), 458–465 (2010).CrossRefGoogle Scholar
  20. 20.
    Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animals Resources, Commission on Life Sciences, National Research Council, National Acad. Press, Washington, 1996).Google Scholar
  21. 21.
    A. A. Shumakova, V. V. Smirnova, O. N. Tananova, E. N. Trushina, L. V. Kravchenko, I. V. Aksenov, A. V. Selifanov, S. Kh. Soto, G. G. Kuznetsova, A. V. Bulakhov, I. V. Safenkova, I. V. Gmoshinskii, and S. A. Khotimchenko, “Toxicological-hygienic characteristics of silver nanoparticles injected into rat gastrointestinal tract,” Vopr. Pitaniya 80(6), 9–18 (2011).Google Scholar

Copyright information

© Pleiades Publishing, Ltd. 2014

Authors and Affiliations

  • O. V. Kalmantaeva
    • 1
  • V. V. Firstova
    • 1
  • V. D. Potapov
    • 1
  • E. V. Zyrina
    • 1
  • V. N. Gerasimov
    • 1
  • E. A. Ganina
    • 1
  • V. A. Burmistrov
    • 2
  • A. V. Borisov
    • 1
  1. 1.State Research Centre of Applied Microbiology and BiotechnologyObolensk, Moscow oblastRussia
  2. 2.Scientific-Production Centre “Vektor-Vita,”NovosibirskRussia

Personalised recommendations